ClinicalTrials.gg
RecruitingNCT05919940Updated Mar 3, 2026

Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO )

An interventional study of Dietary Supplement: additional substitution of protein and Neuromuscular electrical stimulation in ICU Acquired Weakness, Muscle Atrophy and Energy Malnutrition Protein, sponsored by Technical University of Munich. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Technical University of Munich · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Muscular Atrophy with a site in Germany — 7 open to participants now, 8 under way, 1 of them phase 3. Muscular Atrophy · Germany.

Planned enrollment
14th of 21
40 · median 130
Started
2023
with 4 others
No phase
16 of 23
7 open now
Registered
15th of 23
by date
Lead sponsor
1 of 23
Technical University of Munich

Among the 23 studies in Muscular Atrophy with a site in Germany, this one is the 14th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2023, is one of 16 with no phase, and was the 15th registered.

Muscular Atrophy

413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.

Browse Muscular Atrophy studies →

Open to participants now

7 of the 23 studies in Muscular Atrophy with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Muscular Atrophy with a site in Germany, or all of them as a file.
02

Study summary

Intensive Care Unit Acquired Weakness (ICUAW) describes muscle weakness that occurs in around 40% of patients during an intensive care stay. The morbidity and mortality of these patients is significantly increased over a 5-year period. The aim of this study is to investigate the combined effect of early enteral high-protein nutrition and early muscle activation on muscle atrophy in critically ill patients.

The study will include 40 patients (20 intervention, 20 observation) with requirement for enteral nutrition at time of inclusion. In the intervention group the maximum possible level of mobilization is carried out and muscles are activated twice a day using neuromuscular electrical stimulation (NMES). The nutrition plan of the intervention group is based on the applicable guidelines for intensive care medicine with exception of increased protein intake. The control group receives therapy without deviating from the standard according of the DGEM guideline.

The study aims to show that the decrease in muscle mass is significantly less than in the control group (primary hypothesis) via ultrasound of the rectus femoris muscle and in case of given consent muscle biopsy. As secondary hypothesis it is examined whether the combination of early high protein intake and muscle activation improves muscle strength and endurance.

Read the detailed description

Intensive Care Unit Acquired Weakness (ICUAW) describes the clinically diagnosed manifestation of a neuromuscular organ dysfunction. It develops in approximately 40% of all intensive care unit patients amounting to at least 1.2 million patients annually in Germany. All these patients face a broad range of sequeleae and an increased mortality up to 5 years after ICU discharge. A characteristic pathophysiological phenomenon is an early severe muscle atrophy reaching 10% during the first days after ICU admission.

The current preventative and therapeutic approach for ICUAW is a combination of targeted risk factor management as well as early activation of muscles, i.e. neuromuscular electrical stimulation (NMES) and early mobilization as they have been shown to counteract the muscle atrophy and mediate different outcome benefits such as shorter ICU stay.

Nutrition is a key element of our daily life. Protein intake has been shown to affect lean mass and muscle mass. Research into specific nutritional strategies to treat or prevent ICUAW are scarce and the combination with early muscle activation has not been adequately explored.

The study will include 40 patients (20 intervention, 20 observation) who were admitted to an intensive care unit within the last 48 hours. A basic requirement for inclusion is an indication for enteral (via the gastrointestinal tract) nutrition at time of inclusion. In the intervention group, the ability to mobilize is assessed daily and the maximum possible level of mobilization is carried out and additional muscles are activated twice a day using neuromuscular electrical stimulation (NMES). The nutrition plan of the intervention group is based on the applicable guidelines for intensive care medicine. In this study, protein intake is increased in the interventional group. The control group receives therapy without deviating from the standard according to the SOP and DGEM guideline: "Clinical nutrition in intensive care medicine" 2018.

The study aims to show that the decrease in muscle mass is significantly less than in the control group (primary hypothesis) via ultrasound of the rectus femoris muscle and muscle biopsy. As a second hypothesis it is examined whether the combination of early high protein intake and muscle activation improves muscle strength and endurance compared to the control group.

Further exploratory analyses will investigate changes in the skeletal muscle glycogen content, skeletal muscle histology, skeletal muscle gene expression, skeletal muscle protein level, as well as metabolomic changes in blood and urine.

An additional blood sample will be taken after 90 days as part of a follow-up.

03

Conditions studied

  • ICU Acquired Weakness
  • Muscle Atrophy
  • Energy Malnutrition Protein
  • Quality of Life
  • Morphological and Microscopic Findings
  • Metabolic Disturbance

Keywords

  • Early Mobilization and high-protein nutrition
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • critically ill adults (≥ 18 years of age)
  • newly admitted to the ICU (\<48h)
  • mechanically ventilated, expected to remain for at least 72h
  • enteral nutrition is feasible

Exclusion criteria

Exclusion Criteria:

  • a > 30
  • expected death or withdrawal of life-sustaining treatments
  • prior neuromuscular disease (e.g. paresis, myopathies, neuropathies)
  • injury or disease preventing neuromuscular electrical stimulation or early mobilization (e.g., elevated intracranial pressure, unstable spine)
  • a pacemaker or other electronic implant
  • allergy to components of NMES adhesive
  • have been dependent during activities of daily living prior to the hospital admission
  • a language barrier
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Intervention

    High protein substitution plus NMES and EM

    Dietary Supplement: Dietary Supplement: additional substitution of protein · Device: Neuromuscular electrical stimulation · Other: Early Mobilization

  • No intervention
    Control Group

    Nutrition and mobilization are carried out according to standard of care.

Interventions

  • Dietary supplementDietary Supplement: additional substitution of protein

    Day one (admission) no nutrition is applied. Protein target is increased as follows: * to a level of 1,2g/kg/d on day 1 after ICU admission * to a level of 1,4g/kg/d on day 2 after ICU admission * to a level of 1,6g/kg/d on day 3 after ICU admission * to a level of 1,8g/kg/d on day 4 after ICU admission * to a level of 2,0g/kg/d from day 5 onwoards Additional protein is given within 2 hours after mobilization respectively: * to 0,125g/kg/d on day 1 after ICU admission * to 0,2g/kg/d on day 2 after ICU admission * to 0,25g/kg/d on day 3 after ICU admission * to 0,3g/kg/d from day 4 after ICU admission onwoards

  • DeviceNeuromuscular electrical stimulation

    twice daily 60 minutes till day 28 or ICU discharge

  • OtherEarly Mobilization

    at least 20 minutes a day following the SOMS concept. Duration: till 28 day or ICU discharge

06

What researchers measure

Primary outcomes

  1. Change in cross sectional area (ΔCSA) of the rectus femoris

    Change in muscle mass between study inclusion and study day 14; measured as change of the cross sectional area (ΔCSA) of the rectus femoris muscle via ultrasound.

    Time frame: day 1 (study inclusion) and 14 days

Secondary outcomes

  1. change in muscle thickness of the rectus femoris

    change in muscle thickness from study inclusion until 90-day follow-up, measured via ultrasound.

    Time frame: day 1 (study inclusion) until 90-day Follow-up

  2. change in echogenicity of the rectus femoris

    change in echogenicity from study inclusion until 90-day follow-up, measured via ultrasound.

    Time frame: day 1 (study inclusion) until 90-day Follow-up

  3. change of the pennation angle of the rectus femoris

    change of the pennation angle from study inclusion until 90-day follow-up, measured via ultrasound.

    Time frame: day 1 (study inclusion) until 90-day Follow-up

  4. change of the muscle strength, measured by the Medical Research Council score (MRC-score)

    change of the muscle strength, measured by the Medical Research Council score (MRC-score) from study inclusion until 90-day follow-up

    Time frame: day 1 (study inclusion) until 90-day Follow-up

  5. change of the muscle strength, measured by handgrip dynamometry

    change of the muscle strength, measured by handgrip dynamometry from study inclusion until 90-day follow-up

    Time frame: day 1 (study inclusion) until 90-day Follow-up

  6. change in muscle endurance

    change in muscle endurance, measured by the 6-minute walking test up to 90-day follow-up

    Time frame: up to 90 day follow up

  7. change in physical physical function

    change in physical physical function, measured by the Short Physical Performance Battery up to 90-day follow-up

    Time frame: up to 90-day follow-up

  8. development of quality of life

    development of quality of life, measured by the Short Form-36 up to 90-day follow-up

    Time frame: up to 90-day follow-up

  9. change in Skeletal muscle mass

    change in Skeletal muscle mass, measured with bioelectrical impedance analysis up to 90-day follow-up.

    Time frame: day 1 (study inclusion) until 90-day Follow-up

  10. change in extracellular volume

    change in extracellular volume, measured by the Body impedance analysis

    Time frame: day 1 (study inclusion) until 90-day Follow-up

  11. change in the REE (Resting Energy Expenditure)

    change in the REE (Resting Energy Expenditure), measured by indirect calorimetry

    Time frame: day 1 (study inclusion) until 90-day Follow-up

  12. urea-to-creatinine ratio

    urea-to-creatinine ratio from blood sample

    Time frame: day 1 (study inclusion) until 90-day Follow-up

  13. Identify possible predictors of muscle wasting in urine metabolomics at ICU admission

    Among the urine metabolomics that will be measured, identify metabolites or combinations of metabolites whose high or low concentration(s) at ICU admission associate(s) with the amount of muscle loss. These metabolites are candidate biomarkers that could be used to identify individuals at risk of large muscle wasting and may give further insights into the mechanisms of muscle wasting.

    Time frame: day 1 (study inclusion) until 90-day Follow-up

  14. Identify possible predictors of muscle wasting in the blood metabolome at ICU admission

    Among the blood metabolome that will be measured, identify metabolites or combinations of metabolites whose high or low concentration(s) at ICU admission associate(s) with the amount of muscle loss. These metabolites are candidate biomarkers that could be used to identify individuals at risk of large muscle wasting and may give further insights into the mechanisms of muscle wasting.

    Time frame: day 1 (study inclusion) until 90-day Follow-up

Other outcomes

  1. in-hospital mortality

    Mortality during the Hospital stay

    Time frame: until 90-day Follow-up

  2. Hospital LOS

    Length of stay in the hospital

    Time frame: until 90-day Follow-up

  3. ICU-LOS

    Length of stay in the ICU

    Time frame: until 90-day Follow-up

  4. Hospital mortality

    Mortality during Hospital stay

    Time frame: until 90-day Follow-up

  5. Duration of Mechanical ventilation

    Duration of invasive mechanical ventilator dependency

    Time frame: until 90-day Follow-up

  6. ICU mortality

    Mortality during ICU stay

    Time frame: until 90-day Follow-up

  7. enzyme function in the rectus femoris

    Spectrophotometry will be done in muscle samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) and correlation with blood metabolome changes.

    Time frame: according to biopsy inbetween day 1-7

  8. protein content in the rectus femoris

    Western Blot will be done in muscle samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) and correlation with blood metabolome changes.

    Time frame: according to biopsy inbetween day 1-7

  9. geneexpression in the rectus femoris

    qPCR (quantitive polymerase chain reaction) will be done in muscle samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) and correlation with blood metabolome changes.

    Time frame: according to biopsy inbetween day 1-7

  10. Muscle morphology of the rectus femoris

    Light-and Electron-Microscopy will be done in muscle samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) and correlation with blood metabolome changes.

    Time frame: according to biopsy inbetween day 1-7

07

Study locations

2 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified data can be requested on reasonable scientific request and data sharing contract, if necessary.

Supporting information: Study protocol, Informed consent form

Time frame: After publication of scientific manuscript.

Access criteria: Deidentified data can be requested on reasonable scientific request and data sharing contract, if necessary.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Dec 2026, 42 months after the start.

Of 170 non-industry interventional studies with no phase under Muscular Atrophy, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 42 months is above that.

Counting every sponsor, half of 176 studies reached it within 21 months; a quarter within 9 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2023
First posted
Jun 27, 2023
StartActual
Jun 27, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jan 31, 2027
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05919940
Collaborators
Fresenius Kabi, University Medicine Greifswald, Berlin Institute of Health, Universitätsklinikum Ulm, Medical University of Vienna
Responsible party
Prof. Dr. Stefan Schaller, MD (Full Professor, Medical University of Vienna) — Principal investigator
First posted
Jun 27, 2023
Start date
Jun 27, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Mar 3, 2026

Study contacts

Stefan J Schaller, MD
Contact
s.schaller@tum.de
+498941409635
Marian Demitsch
Contact
aai-research@muv.ac.at
Stefan J Schaller, MD
principal investigator · Medical University of Vienna & Charité - Universitätsmedizin Berlin

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion